Innoviva, Inc. Long Term Debt 2010-2024 | INVA
Innoviva, Inc. long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Innoviva, Inc. Annual Long Term Debt
(Millions of US $) |
| 2023 |
$446 |
| 2022 |
$444 |
| 2021 |
$395 |
| 2020 |
$386 |
| 2019 |
$377 |
| 2018 |
$383 |
| 2017 |
$574 |
| 2016 |
$708 |
| 2015 |
$733 |
| 2014 |
$726 |
| 2013 |
$288 |
| 2012 |
$173 |
| 2011 |
$173 |
| 2010 |
$173 |
| 2009 |
$173 |
Innoviva, Inc. Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
$256 |
| 2024-06-30 |
$447 |
| 2024-03-31 |
$447 |
| 2023-12-31 |
$446 |
| 2023-09-30 |
$446 |
| 2023-06-30 |
$445 |
| 2023-03-31 |
$445 |
| 2022-12-31 |
$444 |
| 2022-09-30 |
$444 |
| 2022-06-30 |
$443 |
| 2022-03-31 |
$443 |
| 2021-12-31 |
$395 |
| 2021-09-30 |
$392 |
| 2021-06-30 |
$390 |
| 2021-03-31 |
$388 |
| 2020-12-31 |
$386 |
| 2020-09-30 |
$383 |
| 2020-06-30 |
$381 |
| 2020-03-31 |
$379 |
| 2019-12-31 |
$377 |
| 2019-09-30 |
$389 |
| 2019-06-30 |
$387 |
| 2019-03-31 |
$385 |
| 2018-12-31 |
$383 |
| 2018-09-30 |
$381 |
| 2018-06-30 |
$487 |
| 2018-03-31 |
$485 |
| 2017-12-31 |
$574 |
| 2017-09-30 |
$578 |
| 2017-06-30 |
$639 |
| 2017-03-31 |
$702 |
| 2016-12-31 |
$708 |
| 2016-09-30 |
$719 |
| 2016-06-30 |
$722 |
| 2016-03-31 |
$735 |
| 2015-12-31 |
$733 |
| 2015-09-30 |
$744 |
| 2015-06-30 |
$738 |
| 2015-03-31 |
$732 |
| 2014-12-31 |
$726 |
| 2014-09-30 |
$705 |
| 2014-06-30 |
$738 |
| 2014-03-31 |
$288 |
| 2013-12-31 |
$288 |
| 2013-09-30 |
$288 |
| 2013-06-30 |
$460 |
| 2013-03-31 |
$460 |
| 2012-12-31 |
$173 |
| 2012-09-30 |
$173 |
| 2012-06-30 |
$173 |
| 2012-03-31 |
$173 |
| 2011-12-31 |
$173 |
| 2011-09-30 |
$173 |
| 2011-06-30 |
$173 |
| 2011-03-31 |
$173 |
| 2010-12-31 |
$173 |
| 2010-09-30 |
$173 |
| 2010-06-30 |
$173 |
| 2010-03-31 |
$173 |
| 2009-12-31 |
$173 |
| 2009-09-30 |
$173 |
| 2009-06-30 |
$173 |
| 2009-03-31 |
$173 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$1.132B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
